News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
The move will add new global talent to Cytel’s Strategic Consulting group
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
Plans to double its manufacturing footprint to bolster the growth
Dr. Reddy’s largest manufacturing facility in Bachupally, Hyderabad, joins Global Lighthouse Network of the World Economic Forum
Subscribe To Our Newsletter & Stay Updated
